Authors


Jorge E. Cortes, MD

Latest:

Future Directions in the Management of Acute Myeloid Leukemia

Closing out their discussion on the management of acute myeloid leukemia, expert panelists share their excitement for the future evolution of the treatment landscape.


Jorge E. Cortes, MD, MD Anderson Cancer Center

Latest:

GIMEMA LAL2116, D-ALBA, Updated Results and Prognostic Impact of IKZF1 in Ph+ ALL

Robin Foà, MD, leads a discussion on the primary takeaways from the GIMEMA LAL2116, D-ALBA trial, particularly the prognostic impact of the IKZF1-plus genotype and the Ikaros mutation.



Jorge Garcia, MD

Latest:

Dr. Garcia Discusses the LATITUDE Study in Prostate Cancer

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.


Jorge J. Castillo, MD

Latest:

Dr Castillo on the Rationale for Evaluating Iopofosine I 131 in Waldenström Macroglobulinemia

Jorge J. Castillo, MD, discusses the rationale for evaluating the iopofosine I 131 in Waldenström macroglobulinemia.


Jorge Moscat, PhD

Latest:

Novel Protein Research May Help Unravel Obesity-Cancer Link

Researchers of Sanford Burnham Prebys Medical Discovery Institute indicates that p62 may represent a link connecting obesity, inflammation, and progression of certain cancers.



Jorges E. Cortes, MD

Latest:

Dr. Cortes on Tyrosine Kinase Inhibitors in CML

Jorge E. Cortes, MD, shares his experience with tyrosine kinase inhibitors as treatment of patients with chronic myeloid leukemia.


Jose Baselga, MD, PhD

Latest:

Dr. Baselga on Biomarker Research for Breast Cancer

José Baselga, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses biomarker research for patients with breast cancer.



Jose Leis, MD

Latest:

Dr. Leis on Promising Combo Regimens Being Explored in CLL

Jose Leis, MD, associate professor of Medicine, Mayo Clinic, discusses combination regimens that seem promising and are under investigation in the treatment landscape of chronic lymphocytic leukemia.


Jose M. Pacheco, MD

Latest:

Dr. Pacheco on the Mechanism of Action of Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic NSCLC

Jose Pacheco, MD, discusses the mechanism of action of trastuzumab deruxtecan in patients with HER2-overexpressing metastatic non–small cell lung cancer.


Jose P. Zevallos, MD, MPH, FACS

Latest:

Dr. Zevallos on Molecular Profile of HPV-Positive Oropharyngeal SCC Stratified by Smoking Status

Jose P. Zevallos, MD, MPH, FACS, assistant professor, director of Oncologic Research, University of North Carolina School of Medicine, discusses a study that examined the molecular profile of patients with HPV-positive oropharyngeal squamous cell carcinoma (SCC) stratified by smoking status.


Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine

Latest:

Future Directions for HCC Management

Drs Josep Llovet, Stephen L. Chan, and Andrea Casadei Gardini discuss the future treatment landscape for HCC.



Josep M. Llovet, MD, PhD

Latest:

Dr Llovet on the Efficacy of TACE With or Without Lenvatinib Plus Pembrolizumab in HCC

Josep Llovet, MD, discusses the effiacy of TACE treatment with or without lenvatinib plus pembrolizumab in intermediate-stage hepatocellular carcinoma.


Josep Tabernero, MD, PhD

Latest:

Dr. Tabernero on the Efficacy of Bevacizumab Plus TAS-102 in Refractory mCRC

Josep Tabernero, MD, PhD, discusses findings from the phase 3 SUNLIGHT trial investigating the combination of bevacizumab plus trifluridine/tipiracil vs TAS-102 alone in patients with refractory metastatic colorectal cancer.


Joseph A. Califano, MD

Latest:

Dr. Califano Discusses the Role of Surgery in Head and Neck Cancer

Joseph A. Califano, MD, professor of surgery, University of California, San Diego, discusses the role of surgery in head and neck cancer.


Joseph A. Sparano, MD

Latest:

Dr. Sparano on the Utility of Liquid Biopsies in Breast Cancer

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, professor of Medicine & Obstetrics, Gynecology, and Women’s Health at the Albert Einstein College of Medicine, and associate chairman for Clinical Research in the Department of Oncology at Montefiore Medical Center, discusses the utility of liquid biopsies in breast cancer.



Joseph Alvarnas, MD

Latest:

Dr. Alvarnas on the Importance of Access to CAR T-cell Therapy in Cancer Care

Joseph Alvarnas, MD, discusses the importance of access to CAR T-cell therapy in cancer care.



Joseph Burns

Latest:

Practices in Bundled Payment Program Credit Medical Home Structure for Success

In July, UnitedHealthcare (UHC) reported that an innovative program using bundled payment for cancer care resulted in an impressive 34% reduction in medical costs when compared with costs for a control group


Joseph Chao, MD

Latest:

Dr. Chao on the Utility of MSI as a Biomarker in Gastric/GEJ Cancer

Joseph Chao, MD, discusses the utility of microsatellite instability (MSI) status as a prognostic biomarker in gastric and gastroesophageal cancer.


Joseph Ciccolini, PhD

Latest:

Dr. Ciccolini on Dose Levels of Cetuximab in Head and Neck Cancer

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.


Joseph F. Renzulli, II, MD, FACS

Latest:

Dr. Renzulli on Expanded Access Program With Radium-223

Joseph F. Renzulli, II, MD, FACS, assistant professor of surgery (urology) clinical, Alpert Medical School, discusses the expanded access program in the United States for radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.


Joseph G. Jurcic, MD

Latest:

Dr Jurcic on the Evolution of Combination Therapies in the Management of Myelofibrosis

Joseph G. Jurcic, MD, discusses the evolution of combination therapies in the management of myelofibrosis.



Joseph Jurcic, MD

Latest:

Dr. Jurcic on Lintuzumab and Low-Dose Cytarabine for AML

Joseph Jurcic, MD, professor of Clinical Medicine, director of the Hematologic Malignancies Section of the Hematology/Oncology Division, Columbia University Medical Center, discusses a phase I trial of lintuzumab and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).


Joseph Leach, MD

Latest:

Dr. Leach on Brigatinib in ALK-Positive NSCLC

Joseph Leach, MD, medical oncologist at Minnesota Oncology, discusses the use of brigatinib (Alunbrig) in ALK-positive non–small cell lung cancer (NSCLC).